自体干细胞移植后帕博利珠单抗治疗弥漫大B细胞淋巴瘤的2期研究
本研究为2期多中心单臂试验,评估化疗敏感型复发/难治性弥漫大B细胞淋巴瘤患者自体干细胞移植后接受帕博利珠单抗巩固治疗。主要终点18个月无进展生存率为59%,未达到从60%提升至80%的目标,18个月总生存率93%。
要点
- 帕博利珠单抗200 mg每3周最多8周期,移植后出院21天内开始
- 18个月无进展生存率59%,未达到预设80%的主要终点
核心结论
- 帕博利珠单抗可作为自体移植后巩固治疗安全给药,但无进展生存未达主要终点,不支持开展更大规模验证性研究。
研究设计与样本
- 2期、多中心、单臂研究,纳入化疗敏感型复发/难治性弥漫大B细胞淋巴瘤患者,共29例接受治疗。
主要发现
- 18个月无进展生存率为59%,未达到从60%提升至80%的主要终点。
- 18个月总生存率为93%。
- 62%患者完成全部8个周期治疗。
关键数值与推荐
- 帕博利珠单抗200 mg静脉注射,每3周一次,最多8个周期,移植后出院21天内开始。
- 主要终点为移植后18个月无进展生存率,预设目标从60%提升至80%。
临床怎么用
- 该方案未达主要疗效终点,不推荐在自体移植后常规使用帕博利珠单抗巩固治疗复发/难治性弥漫大B细胞淋巴瘤。
局限性
- 单臂设计,样本量29例,无对照组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Disease relapse remains the leading cause of failure after autologous stem cell transplantation (ASCT) for patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). We conducted a phase 2, multicenter, single-arm study of the anti-PD-1 monoclonal antibody pembrolizumab given after ASCT in patients with chemosensitive DLBCL, hypothesizing that it would improve the progression-free survival (PFS) at 18 months after ASCT (primary endpoint) from 60% to 80%. Pembrolizumab was administered at 200 mg IV every 3 weeks for up to 8 cycles, starting within 21 days of post-ASCT discharge. Twenty-nine patients were treated on this study; 62% completed all 8 cycles. Seventy-nine percent of patients experienced at least one grade 3 or higher adverse event, and 34% experienced at least one grade 2 or higher immune-related adverse event. Overall, 59% of patients were alive and progression free at 18 months, which did not meet the primary endpoint. The 18-month overall survival was 93%. In conclusion, pembrolizumab was successfully administered as post-ASCT consolidation in patients with R/R DLBCL, but the PFS did not meet the protocol-specific primary objective and therefore does not support a larger confirmatory study. This trial was registered at www.clinicaltrials.gov as #NCT02362997.
引用
- Frigault MJ, Armand P, Redd RA, et al. PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation. Blood Adv. 2020. PMID: 31917843. doi:10.1182/bloodadvances.2019000784
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。